
	Ms. Elizabeth Adkins Czerepak served as the Chief Financial Officer of Cancer Genetics, Inc. from January 24, 2011 to March 31, 2014 and also served as its Principal Accounting Officer until March 2014. Ms. Czerepak Co-Founded BIOptima Advisors in May 2009. She was a Managing Partner at Bear Stearns Health Innoventures Management, L.L.C. She is employed at Bear Stearns Asset Management Inc. Ms. Czerepak is the General Partner of the funds comprising the Bear Stearns Health Innoventures Group, since its inception in April 2001. She served as the Vice President of Business Development and a Member of the Executive Board at BASF Pharma and Knoll Pharmaceutical Co., participating in the direction of all operational activities. Prior to BASF, Ms. Czerepak spent nine years at Hoffmann-La Roche in senior positions responsible for licensing, acquisitions, financial analysis, and strategic planning. She served as a Liaison for Roche in managing strategic deal flow from its &ldquo;window on technology&rdquo; investments in the health care-focused venture capital funds of HealthCare Ventures, CW Group, Oxford Bioscience Partners, Advent, HealthCare Ventures, and others. Ms. Czerepak began her pharmaceutical career at Merck and Co., where she was a key member of the team that developed the first comprehensive, simulation-based model for predicting research and development productivity. Ms. Czerepak is a Director at Advancis Pharmaceutical Corp., RAVEN Biotechnologies, Agensys, Inc., AGY Therapeutics, Inc., and PharmAthene, Inc. Ms. Czerepak served as a Director at Affymax, Inc. She received a B.A., magna cum laude, from Marshall University and an M.B.A. in Finance from Rutgers University.
